VIENNA, Austria, June 4 /PRNewswire/ -- EUCODIS Bioscience, a company developing enzymes for the chemical, the pharmaceutical, and other industries, announced today that it has successfully launched its first commercial enzyme, a beta-lactamase. The product is manufactured by EUCODIS Bioscience and can be supplied in a GMP-compliant formulation. The Company will market its beta-lactamase to antibiotics manufacturers to improve quality control, to the diagnostics industry, and to research organizations. The Company estimates that its beta-lactamase has a market potential of up to EUR 5 million.
"The launch of a beta-lactamase for the antibiotics industry and other uses opens a new phase in the development of our organization," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "The EUCODIS Bioscience team has demonstrated its capacity to cover the whole value-chain of an integrated enzyme supplier, from enzyme development, to manufacturing, and to marketing. This success adds momentum to our efforts to bring to market further products that we are currently developing. We will continue to provide our development expertise and our technology to industrial partners that want to increase their research and development efficiency."
About EUCODIS Bioscience
EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.
EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.
EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.
Led by an experienced management team, EUCODIS Bioscience is backed by
Austrian and German institutional ventu
|SOURCE EUCODIS Bioscience|
Copyright©2009 PR Newswire.
All rights reserved